Table 1.
Baseline characteristics of trial cohort in sham and anodal transcranial direct stimulation (atDCS) groups.
| Characteristics | Sham N = 15 | Low-dose atDCS N = 13 | High-dose atDCS N = 14 |
|---|---|---|---|
| Age | |||
| Mean (SD) | 73 (14.1) | 72 (13.3) | 68 (12.6) |
| Sex | |||
| No. (%) Female | 9 (60.0) | 5 (38.5) | 11 (78.6) |
| No. (%) Male | 6 (40) | 8 (61.5) | 3 (21.4) |
| Race | |||
| No. (%) White | 14 (93.3) | 11 (84.6) | 9 (64.3) |
| No. (%) Black | 0 | 2 (15.4) | 3 (21.4) |
| No. (%) Asian | 0 | 0 | 2 (14.3) |
| No. (%) Unknown | 1 (6.7) | 0 | 0 |
| NIHSSa Score (SD) | 11.5 (5.0) | 12.5 (6.1) | 12.8 (4.7) |
| PASb Score (SD) | 4 (1.5) | 4.1(1.1) | 4 (1.2) |
| FOISc Score (SD) | 2.7 (1.3) | 2.8 (1.5) | 3.3 (1.6) |
| Stroke laterality | |||
| No. (%) Right Hemisphere | 9 (60) | 6 (46.2) | 3 (21.4) |
| No. (%) Left Hemisphere | 6 (40) | 7 (53.8) | 11 (78.6) |
| No. (%) Previous Stroke | 2 (13.3) | 2 (15.4) | 1 (7.1) |
| No. (%) Hypertension | 12 (80) | 9 (69.2) | 10 (71.4) |
| No. (%) Diabetes | 6 (40) | 4 (30.8) | 4 (28.6) |
| No. (%) Atrial Fibrillation | 3 (20) | 3 (23.1) | 7 (50.0) |
| No. (%) Coronary Artery Disease | 2 (13.3) | 3 (23.1) | 4 (28.6) |
| TOASTd Classification (percentage) | |||
| Cardioembolism | 5 (33.3) | 6 (46.1) | 7 (50) |
| Large Artery Atherosclerosis | 5 (33.3) | 3 (23) | 3 (21.4) |
| Undetermined Etiology | 4 ((26.6) | 3 (23) | 3 (21.4) |
| Other Determined Etiology | 1 (6.6) | 1 (7.6) | 0 (0) |
| Small Vessel Disease | 0 (0) | 0 (0) | 1 (7.2) |
| Timing in Hours- Mean (SD) | |||
| Time from Onset-to-VFSSe | 80(38) | 91.3 (35.9) | 76.1 (32.6) |
| Time from Onset-to-Enrollment | 84.9 (39.6) | 98.4 (35.4) | 78 (33.1) |
| Time from Onset-to-Intervention | 93.5 (38.8) | 101.6 (32.5) | 84.1 (34.7) |
aNational Institute of Health Stroke Scale.
bPenetration and Aspiration Scale.
cFunctional Oral Intake Scale.
dTrial of Org 10,172 in Acute Stroke Treatment Classification.
eVideofluoroscopic Study.